A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells

The Concise Guide to PHARMACOLOGY 2013/14: Enzymes

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Evolving therapies for liver fibrosis

(2013) Detlef Schuppan et al.   JOURNAL OF CLINICAL INVESTIGATION

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

(2013) Adam J. Pawson et al.   NUCLEIC ACIDS RESEARCH

A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling

(2012) Yuqing Liu et al.   LIVER INTERNATIONAL

Epigenetic Repression of Matrix Metalloproteinases in Myofibroblastic Hepatic Stellate Cells through Histone Deacetylases 4

(2010) Lan Qin et al.   AMERICAN JOURNAL OF PATHOLOGY

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo

(2010) Ki Cheong Park et al.   CANCER SCIENCE

Histone deacetylase inhibition suppresses the transforming growth factor β1-induced epithelial-to-mesenchymal transition in hepatocytes

(2010) Aki Kaimori et al.   HEPATOLOGY

Fibrogenesis in pediatric cholestatic liver disease: Role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment

(2008) Grant A. Ramm et al.   HEPATOLOGY